---
title: "Xinhao Photoelectricity Technology released its performance for the first half of the year, with a net loss attributable to the parent company of 215 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253072956.md"
description: "According to the Zhitong Finance APP, Xinhao Photoelectricity Technology released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 883 million yuan, a year-on-year increase of 10.18%. The net loss attributable to shareholders of the listed company was 215 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 224 million yuan, with a basic loss per share of 1.06 yuan"
datetime: "2025-08-14T14:46:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253072956.md)
  - [en](https://longbridge.com/en/news/253072956.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253072956.md)
---

# Xinhao Photoelectricity Technology released its performance for the first half of the year, with a net loss attributable to the parent company of 215 million yuan

According to the Zhitong Finance APP, Xinhao Photoelectricity Technology (301051.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 883 million yuan, a year-on-year increase of 10.18%. The net loss attributable to shareholders of the listed company was 215 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 224 million yuan, with a basic loss per share of 1.06 yuan

### Related Stocks

- [301051.CN](https://longbridge.com/en/quote/301051.CN.md)

## Related News & Research

- [JDC: Record growth in turnover and EBITDA, with strong outlook driven by new regulation and AI](https://longbridge.com/en/news/296247395.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29](https://longbridge.com/en/news/296393818.md)
- [07:55 ETSAPPHIRE LENSES & WINDOWS PROTECT SENSITIVE ELECTRO-OPTICAL SYSTEMS](https://longbridge.com/en/news/296224371.md)
- [Bermoxel® (Praziquantel 600 mg) Now Available Across All 27 EU Member States Amid Restricted Biltricide® Availability](https://longbridge.com/en/news/296131355.md)